Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD
About Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD
"Centro Malattie dell’Apparato Digerente della Fondazione Policlinico Universitario Agostino Gemelli di Roma. Direttore Professor Antonio Gasbarrini."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD
During the past decade, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on
average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
2018-03-23
2024-04-26
Recruiting
631
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
2019-04-22
2022-11-29
Completed
14,532
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
2020-09-23
2027-05-07
Recruiting
692
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD"
#1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD
According to Clinical.Site data, the most researched conditions in "Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD" are
"Ulcerative Colitis" (3 trials). Many other conditions were trialed in "Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD" in a lesser frequency.
Clinical Trials Intervention Types at Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD
Most popular intervention types in "Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD" are "Drug" (3 trials). Other intervention types were less common.
The name of intervention was led by "Etrasimod" (3 trials) and "Placebo" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD
The vast majority of trials in "Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD" are
3 trials for "All" genders.
Clinical Trials Status at Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD
Currently, there are NaN active trials in "Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD".
undefined are not yet recruiting,
1 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Fondazione Policlinico Universitario Agostino Gemelli IRCCS - CEMAD, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".